NCT06667167 is a Phase 2 clinical trial of Induction Carboplatin in NSCLC (non-small Cell Lung Cancer), sponsored by Nir Peled.

Who is sponsoring NCT06667167?

NCT06667167 is sponsored by Nir Peled.

What drugs are being tested in NCT06667167?

Interventions in NCT06667167: Induction Carboplatin.

What condition does NCT06667167 study?

NCT06667167 studies NSCLC (non-small Cell Lung Cancer).

Is NCT06667167 still recruiting?

NCT06667167 is currently recruiting now. Last updated 17 January 2025.

Last reviewed 2025-01-17 · How we verify

NCT06667167

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+Trodelvy

Recruiting now Phase 2 Last updated 17 January 2025

What this trial tests

Phase 2 trial testing Induction Carboplatin in NSCLC (non-small Cell Lung Cancer) in 21 participants. Currently enrolling.

Timeline

24 December 2024

Primary endpoint
1 November 2027

1 November 2028

Quick facts

Lead sponsor	Nir Peled
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	21
Start date	24 December 2024
Primary completion	1 November 2027
Estimated completion	1 November 2028
Sites	1 location across Israel

Drugs / interventions tested

Induction Carboplatin — full drug profile →

Conditions studied

NSCLC (non-small Cell Lung Cancer) — all drugs for NSCLC (non-small Cell Lung Cancer) →

Sponsor

Nir Peled

Who can join

Adults 18 to 99, any sex, with NSCLC (non-small Cell Lung Cancer). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Induction phase of carboplatin+etoposide+pembrolizumab followed by maintenance of Pembrolizumab+sacituzumab govitecan

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Advances in adoptive cell therapies in small cell lung cancer.
Bragasin EI, Cheng J, Ford L, Poei D, et al · · 2025 · cited 3× · PMID 40160238 · DOI 10.37349/etat.2025.1002302
Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies.
Zhou K, Liu X, Zhu H. · · 2025 · cited 2× · PMID 41185045 · DOI 10.1186/s13045-025-01752-9
Redefining the Fight Against SCLC: Standards, Innovations, and New Horizons.
Kemper M, Reitnauer LE, Lenz G, Evers G, et al · · 2025 · PMID 40647553 · DOI 10.3390/cancers17132256

Verify or expand the search:

Other Nir Peled trials

Trials by the same sponsor.

NCT05698264 — A Pilot Study to Understand the Impact of Therapy With Tumour Treating Fields (TTFields) in NSCLC · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06667167 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nir Peled
Last refreshed: 17 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06667167.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing